Aggressive Versus Indolent Prostate Cancer. We extended these analyses to infer that the intersection of the genes enriched among those down-regulated in ag-gressive human prostate cancer (that is, the lagging edge) and up-regulated in indolent prostate cancer (that is, the leading edge) would Dr. Cooperberg concluded that “emerging biomarkers contribute independent predictive information, and offer great promise to improve prostate cancer risk assessment and reduce overtreatment.”. Overtreatment of prostate cancer patients is a problem in the U.S. The prostate cells form abnormal cells that join into masses known as tumors. Both of these tests on their own, fare well in predicting patient outcomes. CAPRA scores integrate PSA levels, Gleason score, clinical T stage, patient age, and the percentage of prostate biopsy tissue containing malignant cells. 7 Due to its long natural history, prostate cancer has been at the forefront of efforts investigating aggressive treatment in oligometastatic disease. Prostate cancer (PCA) is a molecularly heterogeneous disease with a varied clinical spectrum ranging from indolent to highly aggressive. Combining clinical information from the CAPRA score with the information expressed in either of these genetic scores yielded improved predictions, better than what could be achieved with clinical or genetic information alone. Such overtreatment is costly both economically and physically, as treating prostate cancer can cause unpleasant and long-lasting side effects in some men. On the other hand, indolent prostate cancer is a low-risk, slow-growing and low-volume tumor that can sit in the prostate gland for many years without causing any problems. âThey can really help us decide who has indolent prostate cancer and who should be followed.â There are also some methods of risk stratification that are still being studied. Approximately 30-40% of men who have undergone surgical or other therapeutic interventions to treat their prostate cancers likely had indolent, slow-growing tumors that would never have become a threat to the man’s lifespan or health. Genomic hallmarks of localized, non-indolent prostate cancer Prostate tumours are highly variable in their response to therapies, but clinically available prognostic factors can ⦠Prostate cancer (PCA) is a molecularly heterogeneous disease with a varied clinical spectrum ranging from indolent to highly aggressive. Indolent prostate cancers that pose very low risk to aged men occur frequently and may be detected at biopsy, leading to the contemporary problem of prostate cancer over-diagnosis and over-treatment. Dr. Cooperberg studies various biomarkers as a means to improve or refine the stratification of indolent from aggressive tumors in newly-diagnosed prostate cancer patients. The team has developed a way to classify low Gleason score prostate tumors into indolent and aggressive subgroups based on the expression of genes associated with aging and senescence. Fortunately, they comprise the majority of prostate cancers throughout the ⦠He and colleagues at UCSF developed the CAPRA score as a means to predict whether a patient has low, intermediate, or high risk prostate cancer; the scores generated are used to guide treatment decisions. In his talk at the AACR – PCF Conference, Cooperberg presented results from studies in which several biomarker tests were evaluated for their ability to refine CAPRA and related scores in predicting tumor aggressiveness. They knew that Cooperberg, a urologic oncologist at the University of California, San Francisco (UCSF), was quite likely right—overtreatment of prostate cancer was an important driver of the 2012 decision by the United States Preventative Services Task Force to recommend against routine screening for prostate cancer in men of any age. Overtreatment of prostate cancer patients is a problem in the U.S. In order to distinguish between aggressive and indolent tumors, genomic analysis, proteomic studies, and biomarker measurement were applied. At UCLA, there is a robust active surveillance program, and most patients in the program have indolent prostate cancer. These assays, or tests, assess aggression-associated biomarkers including mutations or alterations in tumor DNA, expression levels of tumor-associated genes, and altered metabolic analytes in prostate cancer tissues, blood, urine, or prostatic secretions, or detected by imaging technologies such as MRI and PET. "Indolent" comes from the Latin word indolens, which means insensitive to pain. This methodology is 80% accurate in predicting the likelihood of progression to fatal disease. Combining clinical information with genetic information yields better outcome predictions, The Myriad Prolaris Assay examines the expression of 31 genes that regulate tumor cell growth in prostate biopsy specimens to predict the risk of lethal disease. At the 2014 AACR – PCF Advances in Prostate Cancer Research Conference, Dr. Matthew Cooperberg demonstrated that adding biomarker tests to current clinical predictors significantly improves the identification of which prostate cancer patients should undergo active surveillance vs. immediate treatment. Indolent prostate cancer is the pet rock of cancers; it doesnât do much, but the upside of that is that it doesnât need to be treated, either. These are called indolent or slow-growing prostate cancers. Go here to learn more or to get a mailed copy. Overtreatment of prostate cancer patients is a problem in the U.S. While there are many types of prostate cancers, urologists usually break them down into aggressive and indolent categories to make it easier to determine the right treatment and to treat various types of cancers effectively. Prostate cancer continues to be a serious healthcare problem with approximately 220,800 new cases reported in the United States in 2015. Many prostate cancers are indolent and unlikely to pose a life threat. Once formed, a tumor can remain at its original location and not spread to any location outside the prostate. This means that a prostate tumor typically takes many years to grow and reach a size that is detectable. However, if the Gleason score is 7 or below, the prostate cancer may be classified as indolent, depending on other patient factors. But if it does, the spread will be local and slow. It can be quite difficult to make the right treatment decisions. Most prostate cancers are relatively slow-growing. Search term. The early detection of asymptomatic prostate cancer has led to the increased incidence of tumours that are unlikely to become symptomatic during life, so called indolent cancers. So for aggressive prostate cancers to be treated successfully, they should be diagnosed early and treatment should be started when the tumors are still in their early stages. These assays, or tests, assess aggression-associated biomarkers including mutations or alterations in tumor DNA, expression levels of tumor-associated genes, and altered metabolic analytes in prostate cancer tissues, blood, urine, or, How this information will ultimately be used by physicians, and communicated to patients in order to understand treatment decisions, will bring additional challenges. When the microscopic exam returns a Gleason score greater than 7 for cancer that has not spread beyond the prostate, the cancer is classified as aggressive and the patient is given the appropriate treatment. Abstract. Our multidisciplinary approach to treatment ensures that even the most aggressive forms of cancer are treated safely and effectively. Prostate Cancer - Predicting Survival, Indolent Cancer, Freedom from Recurrence, Metastasis, and Trifecta Dr. Cooperberg , together with PCF-funded researchers Dr. Peter Carroll and Dr. June Chan at UCSF, led a team that has recently received a highly competitive DOD Transformative Impact Award, which will further develop and validate the use of these biomarker tests, integrate this information with clinical and lifestyle risk factors to improve patient prognosis, and create tools to help physicians explain this information to patients. One late manifestation of PCA is progression to a neuroendocrine phenotype, which is universally lethal with an average survival of less than one year. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death When a patient is diagnosed with prostate cancer, the urologist will take a biopsy of the prostate gland to make sure the cells are checked under the microscope to determine whether the cancer is aggressive or indolent. Both, furthermore, contribute significant, independent prognostic information above and beyond what can be measured clinically using the CAPRA score or related tools. Active surveillance—a program of monitoring low-risk prostate tumors over time for signs of progression, rather than performing immediate treatment—is substantially under-utilized in men with low-risk disease. In fact, patients with indolent prostate cancers can live for 10-20 years without the cancer causing any serious effects on their lives. Even after detection of distant metastases (DM), metastatic prostate cancer is relatively indolent and marked by a long disease course. One of the biggest challenges for researchers has been identifying a way to screen for prostate cancer that can differentiate between indolent and potentially life-threatening cancers. 9, 10 The number of men with indolent disease was estimated by the sum of the probabilities for indolent cancer (ie, cumulative probability). One of the most significant risk factors associated with prostate cancer is aging (13), which represents a balance of antitumorigenic and protumorigenic signals. Dr. Cooperberg , together with PCF-funded researchers. Various cancer cells are examined and their activity graded using the Gleason score. 2. Such biomarkers would allow for more appropriate pre-treatment triage, thus reducing over-treatment of indolent prostate cancer and intensifying treatment for men at high risk for progression to potentially-lethal metastatic disease. Dr. Andrea Miyahira has a PhD in cancer immunology, and is Director of Research at the Prostate Cancer Foundation. How this information will ultimately be used by physicians, and communicated to patients in order to understand treatment decisions, will bring additional challenges. Aggressive cancer is a high-risk prostate tumor that if not treated remains highly active and very likely to spread to areas outside the prostate gland. One late manifestation of PCA is progression to a neuroendocrine phenotype, which is universally lethal with an average survival of less than one year. The Gleason score also helps the urologist to decide the appropriate treatment. The word indolent has two related meanings: 1. January 28, 2014 — “If we don’t fix the problem of prostate cancer overtreatment, we will lose screening.” Those haunting words, spoken by PCF-funded Young Investigator Dr. Matthew Cooperberg last week at the 2014 AACR – PCF Advances in Prostate Cancer Research Conference, in San Diego, had physician and scientist attendees abuzz. The Oncotype DX Genomic Prostate Score (GPS) is a similar test that examines the expression of 17 aggressive tumor-predictive genes in biopsy specimens.